



MATERIAL SAFETY DATA SHEET

Revision date: 28-Sep-2012

Version: 3.0

Page 1 of 8

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-212-573-2222

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161
Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

Material Name: Clindamycin Hydrochloride Capsules

Trade Name:	Cleocin; Dalacin
Chemical Family:	Mixture
Intended Use:	Pharmaceutical product used as antibiotic agent

2. HAZARDS IDENTIFICATION

Appearance:	75 mg - Green 150 mg - Light Blue/Green 300 mg - Light Blue
Signal Word:	WARNING
Statement of Hazard:	Causes severe eye irritation. May cause allergic skin reaction.

Additional Hazard Information: Known Clinical Effects:

Adverse effects associated with therapeutic use include gastrointestinal disturbances such as nausea, dyspepsia, and vomiting and gastrointestinal irritation. Pseudomembranous colitis (manifested by watery diarrhea, urge to defecate, abdominal cramps, low-grade fever, bloody stools, and abdominal pain) may also occur. Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions.

EU Indication of danger: Irritant

EU Hazard Symbols:

Xi



EU Risk Phrases:

R36 - Irritating to eyes.
R43 - May cause sensitization by skin contact.
Hazardous Substance. Non-Dangerous Goods.

Australian Hazard Classification (NOHSC):

MATERIAL SAFETY DATA SHEET

Material Name: Clindamycin Hydrochloride Capsules
Revision date: 28-Sep-2012

Page 2 of 8
Version: 3.0

2. HAZARDS IDENTIFICATION

Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Clindamycin Hydrochloride	21462-39-5	244-398-6	Xi;R36-43	20-30.2
Talc (non-asbestiform)	14807-96-6	238-877-9	Not Listed	*
Magnesium stearate	557-04-0	209-150-3	Not Listed	*
Corn Starch	9005-25-8	232-679-6	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Lactose	63-42-3	200-559-2	Not Listed	*

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire. May include oxides of carbon, nitrogen, sulfur, and chlorine.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards: Not applicable

MATERIAL SAFETY DATA SHEET

Material Name: Clindamycin Hydrochloride Capsules
Revision date: 28-Sep-2012

Page 3 of 8
Version: 3.0

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions:	Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.
Measures for Cleaning / Collecting:	Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.
Measures for Environmental Protections:	Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.
Additional Consideration for Large Spills:	Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling:	Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Wash hands and any exposed skin after removal of PPE. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.
Storage Conditions:	Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Clindamycin Hydrochloride	
Pfizer OEL TWA-8 Hr:	100 µg/m ³
Talc (non-asbestiform)	
ACGIH Threshold Limit Value (TWA)	2 mg/m ³
Australia TWA	2.5 mg/m ³
Austria OEL - MAKs	2 mg/m ³
Belgium OEL - TWA	2 mg/m ³
Bulgaria OEL - TWA	1.0 fiber/cm ³
	6.0 mg/m ³
	3.0 mg/m ³
Czech Republic OEL - TWA	2.0 mg/m ³
	10 mg/m ³
Denmark OEL - TWA	0.3 fiber/cm ³
Finland OEL - TWA	0.5 fiber/cm ³
	5 mg/m ³
Greece OEL - TWA	10 mg/m ³
	2 mg/m ³
Hungary OEL - TWA	2 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
	0.8 mg/m ³
Lithuania OEL - TWA	2 mg/m ³
	1 mg/m ³

MATERIAL SAFETY DATA SHEET

Material Name: Clindamycin Hydrochloride Capsules
Revision date: 28-Sep-2012

Page 4 of 8
Version: 3.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Netherlands OEL - TWA	0.25 mg/m ³
OSHA - Final PELs - Table Z-3 Mineral D:	20 mppcf
Poland OEL - TWA	4.0 mg/m ³
	1.0 mg/m ³
Portugal OEL - TWA	2 mg/m ³
Slovakia OEL - TWA	2 mg/m ³
	10 mg/m ³
Slovenia OEL - TWA	2 mg/m ³
Spain OEL - TWA	2 mg/m ³
Sweden OEL - TWAs	2 mg/m ³
	1 mg/m ³

Magnesium stearate

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Lithuania OEL - TWA	5 mg/m ³
Sweden OEL - TWAs	5 mg/m ³

Corn Starch

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Australia TWA	10 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Bulgaria OEL - TWA	10.0 mg/m ³
Czech Republic OEL - TWA	4.0 mg/m ³
Greece OEL - TWA	10 mg/m ³
	5 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
	4 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Slovakia OEL - TWA	4 mg/m ³
Spain OEL - TWA	10 mg/m ³

Analytical Method:

Analytical method available for clindamycin. Contact Pfizer Inc for further information.

Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Environmental Exposure Controls:

Refer to specific Member State legislation for requirements under Community environmental legislation.

Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands:

Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes:

Wear safety glasses or goggles if eye contact is possible.

Skin:

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection:

If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

MATERIAL SAFETY DATA SHEET

Material Name: Clindamycin Hydrochloride Capsules
Revision date: 28-Sep-2012

Page 5 of 8
Version: 3.0

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Capsule	Color:	Green (75 mg), Light blue / green (150 mg), light blue (300 mg)
Molecular Formula:	Mixture	Molecular Weight:	Mixture

10. STABILITY AND REACTIVITY

Chemical Stability: Stable under normal conditions of use.
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Clindamycin Hydrochloride

Rat	Oral	LD 50	2618 mg/kg
Rat	Sub-tenon injection (eye)	LD 50	279 mg/kg
Rat	Subcutaneous	LD 50	891 mg/kg
Mouse	Oral	LD 50	1479 mg/kg
Mouse	Intravenous	LD 50	143 mg/kg

Lactose

Rat	Oral	LD50	> 10 g/kg
-----	------	------	-----------

Talc (non-asbestiform)

Rat	Oral	LD50	> 1600 mg/kg
-----	------	------	--------------

Magnesium stearate

Rat	Oral	LD50	> 2000 mg/kg
Rat	Inhalation	LC50	> 2000 mg/m ³

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Clindamycin Hydrochloride

Eye Irritation	Rat	No effect
Eye Irritation	Rabbit	Moderate
Skin Irritation	Rat	No effect

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Clindamycin Hydrochloride

MATERIAL SAFETY DATA SHEET

Material Name: Clindamycin Hydrochloride Capsules
Revision date: 28-Sep-2012

Page 6 of 8
Version: 3.0

11. TOXICOLOGICAL INFORMATION

6 Month(s)	Rat	Oral	600 mg/kg/day	NOAEL	No effects at maximum dose
6 Month(s)	Dog	Oral	600 mg/kg/day	LOAEL	Gastrointestinal system
1 Year(s)	Rat	Oral	300 mg/kg/day	NOAEL	No effects at maximum dose
1 Month(s)	Dog	Oral	300 mg/kg/day	NOAEL	No effects at maximum dose

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Clindamycin Hydrochloride

Reproductive & Fertility	Rat	Oral	300 mg/kg/day	NOAEL	Fertility
Embryo / Fetal Development	Mouse	Oral	600 mg/kg/day	NOAEL	Not Teratogenic
Embryo / Fetal Development	Rat	Oral	600 mg/kg/day	NOAEL	Not Teratogenic
Embryo / Fetal Development	Rat	Subcutaneous	250 mg/kg/day	NOAEL	Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Clindamycin Hydrochloride

Bacterial Mutagenicity (Ames)	<i>Salmonella</i>	Negative
<i>In Vitro</i> Micronucleus		Negative

Carcinogen Status:

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.
See below

Talc (non-asbestiform)

IARC:

Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

MATERIAL SAFETY DATA SHEET

Material Name: Clindamycin Hydrochloride Capsules
Revision date: 28-Sep-2012

Page 7 of 8
Version: 3.0

15. REGULATORY INFORMATION

EU Symbol: Xi
EU Indication of danger: Irritant

EU Risk Phrases:
R36 - Irritating to eyes.
R43 - May cause sensitization by skin contact.

EU Safety Phrases:
S22 - Do not breathe dust.
S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
S37 - Wear suitable gloves.

OSHA Label:
WARNING
Causes severe eye irritation.
May cause allergic skin reaction.

Canada - WHMIS: Classifications

WHMIS hazard class:
Class D, Division 2, and Subdivision B.



Clindamycin Hydrochloride
EU EINECS/ELINCS List 244-398-6

Lactose
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
REACH - Annex IV - Exemptions from the obligations of Register: Present
EU EINECS/ELINCS List 200-559-2

Talc (non-asbestiform)
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
EU EINECS/ELINCS List 238-877-9

Magnesium stearate
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
EU EINECS/ELINCS List 209-150-3

Corn Starch

MATERIAL SAFETY DATA SHEET

Material Name: Clindamycin Hydrochloride Capsules
Revision date: 28-Sep-2012

Page 8 of 8
Version: 3.0

15. REGULATORY INFORMATION

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	232-679-6

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R36 - Irritating to eyes.

R43 - May cause sensitization by skin contact.

Data Sources: Pfizer proprietary drug development information. Safety data sheets for individual ingredients.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 15 - Regulatory Information.

Prepared by: Product Stewardship Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet